Stem cell clinics have grown rapidly over the last decade, but not all follow the rules. The FDA has made it clear: if a therapy involves more than “minimal manipulation” or isn’t “homologous use,” it needs premarket approval. When clinics ignore that, the FDA acts.
Warning Letters:
These are often the FDA’s first step. A clinic may receive a letter stating it is violating the Federal Food, Drug, and Cosmetic Act by marketing stem cell products without proper approval. These letters outline the violations and give the business a chance to correct them.
For instance, Liveyon, a distributor of stem cell products, received a warning letter in 2019 over concerns about product sterility and lack of approval.
Court Injunctions & Lawsuits:
When warning letters don’t lead to changes—or when patient safety is at risk—the FDA can escalate enforcement. In 2018, the FDA filed injunctions against two major stem cell providers:
- Cell Surgical Network (CSN):
A good example is the Cell Surgical Network (CSN), a California-based group of clinics that processed patients’ fat-derived stem cells for conditions like arthritis and neurological disorders. In 2021, a federal court granted the FDA’s request for a permanent injunction, forcing CSN to stop offering those treatments.
- U.S. Stem Cell Clinic:
Another case: U.S. Stem Cell Clinic in Florida, which was sued after offering stem cell injections that led to some patients going blind. The FDA won that case, too—showing courts are supporting the agency’s push for stricter oversight.
Why This Matters:
These actions show that even high-profile clinics are not immune. Enforcement helps ensure that therapies marketed to patients meet established standards of safety and efficacy.
Other Sources for Context:
Why it’s helpful: You can see exactly what the FDA says in its letters—great for spotting trends in enforcement.
